<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2002</study_start_year><condition>Carcinoma</condition><condition>Colorectal Neoplasms</condition><condition>Colonic Neoplasms</condition><condition>Neoplasms</condition><condition>Cancer</condition><disease>Carcinoma</disease><disease>Colorectal Neoplasms</disease><disease>Colonic Neoplasms</disease><disease>Neoplasms</disease><disease>Cancer</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2007471</full_dataset_link><location>United States</location><study_start_month>5</study_start_month><keyword>Epothilone B</keyword><keyword>Neoplasm</keyword><keyword>Colorectal</keyword><keyword>Rectal</keyword><keyword>Intravenous</keyword><keyword>Rectum</keyword><keyword>Epothilone</keyword><keyword>Tumor</keyword><keyword>Tumour</keyword><keyword>Colon</keyword><keyword>Epothilones</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>EPO906 Therapy in Patients With Advanced Colorectal Cancer</name><description>This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause colorectal cancer.</description><dates><creation>2002-05-15</creation></dates><accession>2007471</accession><cross_references><ClinicalTrials___gov>NCT00035087</ClinicalTrials___gov></cross_references></HashMap>